Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Devices

Butterfly Network, Inc. logoButterfly Network, Inc.

BFLY · the NYSE · USD · Market cap $1.6B · 220 employees

Butterfly Network, Inc.

FAIL · Does not pass the screen
5.75 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price5.75 USD at the 17 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 17 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 8.72)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $10.00 to $12.16, base estimate $10.50 (screen dated 2026-11-17).

Current read
Distribution ?
Undervalued · screened 2026-11-17
  • Trend Distribution
  • Insiders insiders sold, $350,000, latest filing 2026-11-11
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 8.72, read 2026-11-13
  • Ethical does not pass the values gate
Price5.75 USD
Fair value10.50
Ethical score70.0/100
Value readUndervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-12Read Distribution7.14-19.5% to today ✓Markdown gives way to Distribution
2026-10-26Read Markdown6.81-15.6% to today ✓Distribution gives way to Markdown after a 13% slide in 4 days
2026-10-22Read Distribution7.85-26.8% to today ✓Markup gives way to Distribution after a 17% slide in 9 weeks
2026-08-23Read Markup9.45-39.2% to today Markdown gives way to Markup after a 71% rise in 7 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Butterfly Network, Inc. holds its Distribution at $5.75. Elevated stress, defensive posture warranted, held for 12 days.

As held on the ledger · 2026-11-17
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 12 days
Price at the screen$5.75
ValuationN/A trailing · -89.93 forward price to earnings
Values screenFAIL · score 70.0
Beta2.12
The Workings

Five Screens, Shown in Full

Does not pass. Accounts receivable

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 6.88% Below 33% Interest-bearing debt is just 6.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 59.77% Below 49% Money owed to the company is 59.8% of assets, above the 49% limit. Fail
Revenue purity 6.06% Below 5% 6.1% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Butterfly Network,'s business is fine, but its receivables are about 60% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when BFLY's ethical verdict changes

Today BFLY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 45% discount to our $10.50 fair value, 51.70% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

10.00Conservative10.50Base case12.16Growth case 5.75Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 45.2% discount to the base estimate.

The Street's Range
10.00Street low 10.50Street average 15.00Street high 5.75Price

Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +83% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $10.50, with a range of $10.00 to $12.16, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Handheld Scanner Promise Collides With Heavy Losses

A doctor in a remote clinic reaches for a probe the size of a smartphone rather than wheeling out a bulky machine. Butterfly Network built exactly that device and revenue is rising twenty five percent, yet the business still posts a seventy four percent negative profit margin and negative thirty five percent return on equity. The shares sit above our fair value with no margin of safety and a deeply negative forward earnings multiple.

Growth in portable ultrasound looks attractive on paper but four analysts see no consensus upside and the company has yet to prove it can convert device sales into sustainable profits. Unknown competitive position and execution risk on scaling leave the investment case thin despite the ethical screen clearing cleanly.

High cash burn and uncertain hospital adoption keep the risk profile elevated. The setup offers little reason to get involved at current levels.

Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-89.9x
EPS, trailing-0.21
EPS, forward-0.07
Revenue growth+51.7%growing very fast
Profit margin-43.6%currently unprofitable
Return on equity-27.7%not currently earning a positive return on equity
FCF yield-0.43%
Debt to equity0.10minimal debt: a conservative balance sheet
Current ratio3.58comfortably covers its short-term bills
Beta2.12much more volatile than the market
Short interest, float0.16%
52-week range1.90 - 10.21
Market cap$1.6B
Employees220

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

BFLY trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Distribution · changed $7.14 +5.5% Entry 18

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter.

2026-11-05 Markdown $6.77 -13.3% Entry 17

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter.

2026-10-29 Markdown $7.81 +14.7% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 14.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Markdown $6.81 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Markdown $6.81 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markdown · changed $6.81 +0.0% Entry 13

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Distribution $6.81 +0.0% Entry 12

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 48% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-24 Distribution $6.81 +0.0% Entry 11

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 48% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Distribution $6.81 -13.2% Entry 10

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 48% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Distribution · changed $7.85 +0.0% Entry 9

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 48% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $6. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on BFLY

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in BFLY's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · BFLY
DateInsiderTitleTypeSharesValue
2026-11-11 Doherty John N. EVP, CFO S - Sale 50,000 $350,000
2026-10-06 Devivo Joseph Pres, CEO S - Sale 35,790 $358,616
2026-09-22 Devivo Joseph Pres, CEO S - Sale 5,980 $59,867

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $4.20 +28.7% · $1,287 +28.7%
2 months $4.11 +31.5% · $1,315 +31.5%
3 months $3.64 +48.5% · $1,485 +48.5%
6 months $3.08 +75.5% · $1,755 +75.5%
1 year $2.61 +107.1% · $2,071 +107.1%
2 years $0.95 +469.0% · $5,690 +469.0%
3 years $2.17 +149.1% · $2,491 +149.1%
5 years $14.11 -61.7% · $383 -61.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BFLY does next, these words stay.

Butterfly Network, Inc. · BFLY · Distribution · $5.75
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.